Trial Profile
Rivaroxaban Acute Stroke Safety Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2016
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Stroke; Stroke complications; Transient ischaemic attacks
- Focus Therapeutic Use
- Acronyms RASS
- 24 May 2016 Results published in the Stroke
- 04 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Dec 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Jan 2016 as reported by ClinicalTrials.gov.